Tiziana Life Science plc, of London, said its research agreement with Cardiff University, focused on the development of Bcl-3 inhibitors for cancer, led to the identification of a lead candidate, CB1, with antimetastatic activity and in vivo efficacy and safety. The company said it plans to file an investigational new drug application and move CB1 into the clinic before the end of this year.